
According to data from Benzinga Pro, during Q1, PTC Therapeutics's (NASDAQ:PTCT) reported sales totaled $148.74 million. Despite a 11.54% increase in earnings, the company posted a loss of $126.73 million. PTC Therapeutics collected $165.23 million in revenue during Q4, but reported earnings showed a $143.26 million loss.